What is the daily abdominal injection drug for osteoporosis and what is its risk profile for someone who has never broken a bone

The daily injectable osteoporosis drug is teriparatide (Forteo), a parathyroid hormone analog that builds bone. For someone who has never broken a bone, the risk-benefit is not favorable.

The evidence for teriparatide comes from a single large trial funded by the manufacturer, Eli Lilly, which enrolled about 1,637 postmenopausal women with osteoporosis and prior vertebral fractures [1]. That trial showed a 65% reduction in new vertebral fractures (from about 7 in 100 on placebo to about 2 in 100 on teriparatide) [1]. But the trial population was women who had already fractured. There is no randomized trial testing teriparatide in people who have never broken a bone. The drug also causes hypercalcemia in about 11% of users at the standard 20 µg dose, and the 40 µg dose caused it in 28% [1]. Long-term safety data beyond 18 months is thin, and the drug carries a boxed warning about a bone cancer risk seen in animal studies.

For a person with no prior fracture, the absolute risk of a first osteoporotic fracture is much lower than the risk of a second fracture in someone who has already broken one. The number needed to treat to prevent one fracture in a low-risk population is large, while the side effects—nausea, leg cramps, dizziness, and the calcium spike—are immediate and guaranteed for a subset. The manufacturer-funded trial did not compare teriparatide to a true untreated control for people without prior fracture, so the benefit in that group is assumed, not proven.

My call: for someone who has never broken a bone, the evidence does not support starting teriparatide. The benefit is unproven in that population, and the side effect burden is real. Confidence: moderate.